(0.19%) 5 141.25 points
(0.18%) 38 510 points
(0.27%) 17 894 points
(-0.92%) $83.08
(1.66%) $1.955
(-0.30%) $2 340.10
(0.80%) $27.47
(0.25%) $924.40
(-0.15%) $0.933
(-0.04%) $11.02
(-0.19%) $0.799
(0.99%) $92.79
@ $1.160
发出时间: 14 Feb 2024 @ 22:35
回报率: -5.17%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 0.00 %
Live Chart Being Loaded With Signals
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases...
Stats | |
---|---|
今日成交量 | 351 535 |
平均成交量 | 1.47M |
市值 | 192.92M |
EPS | $0 ( 2024-03-05 ) |
下一个收益日期 | ( $-0.0300 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.86 |
ATR14 | $0.00300 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Rojkjaer Lisa | Buy | 187 500 | Employee Stock Option (right to buy) |
2024-03-27 | Rojkjaer Lisa | Buy | 0 | |
2024-02-28 | Schorno Dean L | Buy | 78 500 | Employee Stock Option (right to buy) |
2024-02-28 | Schorno Dean L | Buy | 62 500 | Employee Stock Option (right to buy) |
2024-02-28 | Santos David A | Buy | 80 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
93.23 |
Last 98 transactions |
Buy: 9 654 000 | Sell: 304 047 |
音量 相关性
Rigel Pharmaceuticals Inc 相关性 - 货币/商品
Rigel Pharmaceuticals Inc 财务报表
Annual | 2023 |
营收: | $116.88M |
毛利润: | $109.77M (93.92 %) |
EPS: | $-0.140 |
FY | 2023 |
营收: | $116.88M |
毛利润: | $109.77M (93.92 %) |
EPS: | $-0.140 |
FY | 2022 |
营收: | $120.24M |
毛利润: | $118.49M (98.55 %) |
EPS: | $-0.360 |
FY | 2021 |
营收: | $149.24M |
毛利润: | $148.15M (99.27 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。